June 16, 2014 marked a significant milestone for Apricus with the launch of Vitaros® in the United Kingdom by our partner Takeda. This launch, and the subsequent launches expected to follow in Europe and Canada over the remainder of 2014, represent our commitment to bringing novel products such as Vitaros® to patients in therapeutic areas of significant unmet need. Moreover, this accomplishment marks the end of our Company’s transition which began in 2013, and the beginning of a new era at Apricus characterized by a stronger, more disciplined and more focused organization intent on building value for the benefit of patients, healthcare providers, employees, and importantly stockholders.
Looking forward, we continue to support our partners’ efforts to bring Vitaros® to market outside of the United States. In parallel, we have established and will continue to build a diversified product pipeline starting with the initiation of a Phase 2a clinical trial in the third quarter of 2014 for RayVaTM, our product candidate for the treatment of Raynaud’s Phenomenon secondary to scleroderma. Our goal in building our pipeline is to focus on areas of unmet need in men’s and women’s health, with products with which we can build strategic value through development and commercialization in the United States while working through partnerships internationally.
As the second half of 2014 draws to a close, I am pleased with our progress in delivering on the commitments we made to you earlier this year—to launch Vitaros in Europe, advance our product pipeline, including making solid progress on our Vitaros room temperature device program and filing an Investigational New Drug application to begin clinical studies for RayVa, strengthening our Board of Directors and management team and being good stewards of our strategic resources. We have much more to accomplish in 2014, but I firmly believe that we are on a path to creating long-term value for our shareholders. Thank you as always for your continued support, and I look forward to updating you again in August when we report our second quarter 2014 financial results.
Richard W. Pascoe Chief Executive Officer
Our product, Vitaros®, is a topical cream for the treatment of erectile dysfunction. Vitaros® is locally applied and contains alprostadil plus our novel excipient.
We partner with world-class pharmaceutical
companies who share our passion for improving
men’s and women’s sexual health.